GAITHERSBURG, Md.--(BUSINESS WIRE)--Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, today announced that its subsidiary Intercell USA, Inc. has formally changed its name to Valneva USA, Inc. (Valneva USA). Intercell USA was acquired by Valneva SE (Lyon, France) in May 2013 and has been operating as a fully owned subsidiary. Additionally, the company has taken control of full U.S. marketing and distribution rights for the IXIARO® vaccine, which is indicated for prevention of disease caused by Japanese Encephalitis, a mosquito-borne virus found in Asia that causes inflammation of the brain (encephalitis).
Charles Daily, General Manager, U.S., commented, “Japanese Encephalitis is a potentially devastating and deadly disease for travelers visiting Asia. In many countries where travelers are visiting, local individuals have been vaccinated starting at a very young age. Yet many travelers don’t seek preventative treatment with a vaccine, resulting in a lower immunization rate for U.S. travelers compared to certain European countries. By taking full control of IXIARO® and building out our commercial structure in the U.S., we intend to increase disease awareness and product access to doctors and travelers and improve immunization rates.”
Valneva has successfully established its own commercial infrastructure in key international travel markets over the past two years after it regained global distribution rights of IXIARO® in June 2015. The Company has been distributing the vaccine in the U.S. directly to its largest customer, the U.S. military, and in 2015 entered into an exclusive marketing and distribution agreement for the U.S. private market with a leading local distributor. With the recent expiration of this exclusivity, Valneva now has full commercial control of IXIARO® in the United States and is building a stronger commercialization structure through its subsidiary Valneva USA, Inc., with a new dedicated sales and marketing team, a broader distribution network, and improved packaging that is reduced in size by 30 percent to help with customer storage.
To learn more about how you can purchase IXIARO® please call 866-223-7118.
Valneva’s Japanese Encephalitis vaccine is indicated for active immunization for the prevention of the disease for people who travel to, or live in, endemic areas. It has received marketing approval in the U.S., Europe, Canada, Hong Kong, Singapore, and Israel under the trade name IXIARO® and in Australia and New Zealand where it is marketed as JESPECT®. It is the only vaccine available to the U.S. military for Japanese Encephalitis. IXIARO® is approved for use in individuals two months of age and older in the U.S. and EU member states, Norway, Liechtenstein, Iceland, Singapore, Hong Kong, and Israel. In all other licensed territories, IXIARO®/JESPECT® is indicated for use in persons 18 years of age and above.